Wells Fargo lowers American Well stock price target to $12 on revised growth outlook

Published 07/08/2025, 11:34
Wells Fargo lowers American Well stock price target to $12 on revised growth outlook

Investing.com - Wells Fargo (NYSE:WFC) reduced its price target on American Well Corp . (NYSE:AMWL) to $12.00 from $15.00 on Thursday, while maintaining an Overweight rating on the telehealth company’s stock. The company, currently trading at $7.86, has shown strong momentum with an 8.41% return year-to-date, according to InvestingPro data.

The price target adjustment reflects Wells Fargo’s revised long-term revenue projections for American Well, commonly known as Amwell, based on its discounted cash flow (DCF) model.

Wells Fargo now forecasts American Well will reach $325 million in revenue by 2031, down from its previous estimate of $337 million, representing a 5% six-year compound annual growth rate (CAGR).

The financial institution’s model also anticipates American Well achieving adjusted EBITDA margins of 12% by 2031, indicating gradual profitability improvement for the telehealth provider.

Wells Fargo’s DCF valuation model for American Well incorporates a 3% terminal growth rate and an 8% required return, factors that contributed to the revised $12 price target.

In other recent news, Amwell reported a significant increase in its total revenue for the second quarter of 2025, reaching $70.9 million, which marks a 13% rise compared to the same period last year. This financial performance improvement is attributed to the company’s strategic initiatives in AI and digital healthcare solutions. There were no mergers or acquisitions reported for Amwell in this period. Additionally, there have been no recent analyst upgrades or downgrades for the company. The company’s latest developments reflect its focus on enhancing its digital offerings. Investors may find these revenue figures particularly noteworthy. These recent developments highlight Amwell’s ongoing efforts to strengthen its market position in the digital healthcare sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.